We performed a systematic review on the neurological complications of chikungunya virus. Such complications are being reported increasingly, owing primarily to the scale of recent epidemics but also to a growing understanding of the virus' neurovirulence. We performed a thorough literature search using PubMed and Scopus databases, summating the data on all published reports of neurological disease associated with chikungunya virus. We appraised the data for each major condition in adults, children, and neonates, as well as evaluating the latest evidence on disease pathogenesis and management strategies. The review provides a comprehensive summary for clinicians, public health officials, and researchers tackling the challenges associated with this important emerging pathogen.
1. The agent must be demonstrable in every case of the disease.
2. The agent is not present in other diseases.
3. After isolation in culture, the agent must be able to produce the disease in experimental animals. 4 . The agent can be recovered from the experimental animal.
There are clear limitations to these in modern microbiology. For example, we know now that certain pathogens can cause multiple diseases, and indeed certain diseases can be caused by more than 1 pathogen (postulates 1 and 2). Furthermore, modern technologies such as polymerase chain reaction (PCR) assays have increased our detection rate of certain pathogens over isolation in culture (postulate 3).
We therefore adapt these postulates today in studies regarding causality. Neurological disorders associated with arbovirus infection have an added layer of complexity, owing to the different samples used for testing for the presence of the viruses. The strongest evidence of causality comes from demonstrating that the virus is in the central nervous system (CNS), which is most often shown by detecting viral RNA in the CSF by PCR; alternatively, the virus may be cultured. In fatal cases, autopsy material may be positive by PCR. For many patients, the virus has cleared from the CSF by the time they present; in which case, the detection of CSF IgM antibody by enzyme-linked immunosorbent assay is considered diagnostic. Interpretation is complicated for flavivirus infections because a positive Zika-IgM test can result from crossreactivity of serum containing antibodies against dengue virus.
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Because chikungunya is an alphavirus, there is no serological crossreactivity with the flaviviruses, making diagnosis more straightforward (in areas where other alphaviruses are not circulating). It is not known for how long virus, RNA, or IgM remains detectable in chikungunyaassociated neurological disease, and whether this differs for the different neurological disorders. By analogy with similar arboviruses, we might expect the virus to be detectable for the first few days of illness, at which point it is replaced by antibody, which remains for weeks to months. Chikungunya virus is more readily detected by PCR or culture in the blood, because of its long and high viraemia; IgM antibody can also be detected in the blood. However, a positive blood test in a patient with neurological disease does not necessarily mean the virus caused the disease; infection may be coincidental, and care must be taken to exclude other possible causes. The virus can also be detected in urine, saliva, semen, and milk, [22] [23] [24] but the same caveats apply.
| CLINICAL FINDINGS
Seroprevalence studies have reported a range of asymptomatic rates of chikungunya infection, from 3% to 47%. 25 In acute symptomatic infection, following an incubation period of approximately 3 days, 26 there is an abrupt onset of fever, headache, rash, arthralgia, and myalgia, which typically last for 1 to 2 weeks. 27 After this, seroconversion likely confers lifelong immunity. 28 As well as neurological manifestations, chikungunya virus is associated with complications of the cardiovascular, renal, respiratory, hepatic, gastrointestinal, and adrenal systems, sometimes collectively referred to as "atypical features." [29] [30] [31] However, a disorder of the nervous system appears to be the most common severe complication of chikungunya infection (Table 1) . In 2 studies investigating manifestations of chikungunya in patients requiring intensive care, a neurological disorder was the primary issue in 61% 32 and 79% 33 of chikungunya-infected patients.
FIGURE 1 Search strategy to identify publications on neurological complications of chikungunya
In chikungunya-associated neurological disease, the clinician must be vigilant for other complications in the same patient, a pattern also described in dengue but rarely in Zika infection. Amongst 99 cases of chikungunya-associated neurological disease described in a study in India, 69 also had other complications involving, for example, the renal, hepatic, and respiratory systems. 30 These patients should be managed using a multidisciplinary approach.
| NEUROLOGICAL MANIFESTATIONS
The literature on neurological manifestations of chikungunya reflects that of the disease activity itself, with 5 publications between 1964
and 1971 and 89 since 2005, comprising 27 case reports, 48 case series, 1 case-control study, 3 cohort studies, 1 cross-sectional study, and 14 pathogenesis studies ( Figure 1) ; autopsy data were included in one report found. 34 Table 2 provides a summary of all cases of reported chikungunya-associated neurological disease. In total, we found 856 cases of chikungunya-associated neurological disease in the literature; 796 (93.0%) were in adults and children infected directly via mosquito, 60 (7.0%) were in neonates infected vertically from mother to child ( Figure 2 ). Because patients were investigated to variable extents, we have categorised them according to the presenting clinical syndromes of encephalopathy, myelopathy, neuropathy, combinations of these, and neuro-ocular disease; we then provided diagnoses, treatment, and outcome where available. A limitation of our study was that we could not incorporate diagnostic criteria, given the range of information available amongst all the cases published. The most common clinical presentation of neurological disease associated with adult and child chikungunya infection was encephalopathy; it accounts for 322 (40.5%) of the 781 patients described. Excluding ocular disease, 474 (77.3%) of all adult and child cases had a pure CNS disorder, 82 (13.4%) had a pure peripheral nervous system disorder, and 57 (9.3%) had a disorder of both the CNS and peripheral nervous system.
Cases in which coinfection of chikungunya with another neurovirulent arbovirus was detected are not included in Table 2 It has been suggested that severe complications of chikungunya infection typically arise in those with co-morbidities. 96 The above epidemiological study describing 610 atypical cases of chikungunya infection showed that underlying respiratory disease, cardiac disease, and hypertension were all independently associated with severe complications, including neurological disease. 29 However, a study from India of 124 atypical chikungunya cases did not identify co-morbidity as a significant risk factor for systemic complications or fatality 30 ; similarly, in a case series of chikungunya-associated GBS, 6 (67%) of 9 cases did not have any co-morbidities. 70 Anterior uveitis (11) In one study from Réunion Island, where the authors were careful to accurately define encephalitis using the international criteria, the estimated cumulative incidence rate for chikungunya-associated Symptoms of encephalitis begin between 0 and 13 days following the onset of systemic features of infection (see Table 2 ). As is the case in other arboviral encephalitides, a CSF pleocytosis is not always seen. 40 any imaging abnormalities at all. 37, 40 Although there are non-specific slowing of brain waves in some patients, there is no specific electroencephalogram pattern. 40, 50 In the Réunion Island study, 7 of the 57 patients (aged 4 d-88 y) with either encephalopathy or encephalitis died in hospital or shortly after discharge; of the 10 adults followed up after 3 years, 3 had FIGURE 2 Presentations of nervous system disease associated with chikungunya infection FIGURE 3 Global distribution of chikungunya virus and countries/territories with reported associated neurology. Key: adult and child neurological disease associated with chikungunya infection; vertically acquired neurological disease in the neonate associated with chikungunya infection. *unclear date of case(s), year refers to year of publication. Data regarding global distribution of chikungunya virus acquired from the Centers for Disease Control and Prevention website 95 persistent neurological sequelae in the form of epilepsy, postinfectious dementia, and cognitive disorder. 37 Taking into account the attrition in the follow-up cohort, a range from 18% to 43% of patients were estimated to have neurological sequelae. Similarly, a paediatric series from the same outbreak reported 5 (31%) of 16 children with chikungunyaassociated encephalopathy or encephalitis had residual neurological deficit, whilst 2 (13%) died. 40 From our literature review, of the 127 patients cases for whom follow-up data were reported, 62 (48.8%) had complete or near-complete recovery, 25 (19.7%) had residual neurological deficit, and 40 (31.5%) died.
| Myelopathy and myelitis
Chikungunya virus can cause myelopathy, symptoms of spinal cord disease, which may present with limb weakness, sensory changes, hyperreflexia, and bowel and bladder disturbances, depending on the level of the lesion and extent to which the cord is involved. If cord inflammation is confirmed by MRI, a CSF pleocytosis, or elevated CSF IgG index, showing local immunoglobulin production, then it is classified as myelitis. 106 The incidence of spinal cord disease after chikungunya infection is not known, but it is likely to be less than that of encephalopathy,
given that the 90 cases described in the literature comprise less than a third of the 322 cases of encephalopathy. Myelopathy and myelitis usually occur as part of more widespread neurological disease. Of the 90 patients identified, 47 had myelopathy as part of more widespread CNS disease, with encephalopathy or encephalitis; for 48, there was also peripheral nervous system disease in the form or radiculopathy or neuropathy; just 19 patients had a pure myelopathy syndrome.
Spinal cord disease typically presents 0 day (Mehta et al, unpublished findings) to 3 weeks after the first clinical feature of infection (fever, arthralgia, or rash). 41 Patients present with weakness in 2, 3, or 4 limbs, sometimes accompanied by one or more of paraesthesia in the limbs, a sensory level, or urinary retention. In our literature review, of the 12 patients with a pure myelopathy where CSF data were provided, 6 (50%) had a CSF pleocytosis. Similarly, MRI abnormalities are variable. They may range from changes "suggestive of demyelinating pathology" to extensive T2/fluid-attenuated inversion recovery hyperintensity from the cervicomedullary junction to the C6 level. 60 No deaths have been reported for chikungunya-infected patients with a pure myelopathy syndrome; follow-up data were reported for 13 patients, 11 of whom improved, although the extent of this was often unclear. 
| Guillain-Barré syndrome
Chikungunya-associated peripheral neuropathy without CNS disease has been described for 72 patients in case reports or series, the majority of whom were described as having GBS. In one series of 4 patients with acute flaccid paralysis, no CSF or neurophysiology results were reported, making diagnosis difficult. 69 Other causes of acute flaccid paralysis, such as anterior myelitis, have not yet been reported in association with chikungunya virus.
Two studies from Réunion Island showed an increased incidence of GBS following a large outbreak of chikungunya. One from the 2014 to 2015 outbreak reported 9 patients with chikungunya-associated GBS, representing a 4-to 9-fold increase in the island's annual GBS incidence. 70 The increase in the incidence of GBS following the 2006 chikungunya virus outbreak on Réunion Island was estimated to be around 22% compared with the year before. 68 A study from Martinique and Guadeloupe also showed an increase in incidence of GBS following the 2014 chikungunya virus outbreak, but to a lesser extent (2-fold). 71 Clinically, chikungunya-associated GBS resembles GBS associated with other infections such as Campylobacter jejuni, presenting with symmetrical, bilateral flaccid weakness, often with paraesthesia and/ or cranial nerve palsy. 109 The 4 reports in the literature detailing the time interval between chikungunya infection and onset of neurological features describe a prodrome of 3 to 17 days, compatible with a parainfectious or postinfectious syndrome (Table 2) . 67, 68, 73 Unlike infections such as C. jejuni, which is associated with a more severe pure motor variant of GBS, 110 chikungunya appears to be associated with the full range of GBS variants, as determined by neurophysiological studies, including disorders of motor and sensory axons, and myelin sheaths, sometimes in combination (see Table 2 ). Further investigation is required to determine risk factors and markers for the different GBS variants, including antiganglioside antibodies.
For the 36 cases where treatment was described, 28 (78%) received intravenous immunoglobulin, 2 (6%) intravenous immunoglobulin and plasma exchange, 4 (11%) intravenous methylprednisolone, and 2 (6%) plasmapheresis. Forty (87%) of the 46 cases for whom follow-up data were available improved. In some cases, this was rapid; in most, it had occurred by 3 months.
| Ocular complications
Although photophobia and conjunctivitis are associated with the acute phase of chikungunya infection, 111 many later ocular complications have been described up to 12 weeks after infection, which may require emergency management. These include disease of the uvea, retina, and optic nerve. As well as inflammation, other pathologies have been described, including retinal detachment, intraretinal haemorrhage, and branch retinal artery occlusion (Table 2) . 38, 75 Our literature review found 78 cases of ocular complications of chikungunya infection.
In a retrospective study from India of 37 Indian patients with acute ocular manifestations and IgM-confirmed chikungunya infection, uveitis was the most common diagnosis, occurring in 16 (43%) patients; 75 48 controls from the chikungunya-endemic area, selected from patients attending the hospital for nonacute problems including cataract and refractive error, were all negative for chikungunya IgM.
Recovery was variable-of the 26 patients followed up, the visual acuity improved in 11 (42%), remained the same in 12 (46%), and worsened in 3 (12%). Overall, of the 67 patients with ocular disease we identified for whom follow-up data were reported, 46 (69%) recovered well, whereas 21 (31%) showed minimal or no improvement.
Although most of the serious ocular complications occur days to weeks after the acute chikungunya infection, in one report, 5 of 14 optic neuritis cases occurred simultaneously with the systemic disease onset. 74 This suggests a more direct viral effect may be important, as well a postviral immune response.
Disease relapse has been reported in one report, which described bilateral uveitis and retinal detachment, with loss of visual acuity starting 4 days after symptoms of chikungunya infection. 82 Having received a week's course of oral and topical steroids and recovered within 6 weeks, the patient re-presented 3 months later with floaters and keratic precipitates; clinicians should be vigilant for relapse in such cases.
| Disease affecting multiple components of the nervous system
As well as the distinct syndromes described above, chikungunya infection is associated with complex diseases involving multiple parts of the nervous system causing, for example, encephalomyelopathy (23 patients identified in our literature review), myeloneuropathy (24) , and encephalomyeloneuropathy (24) . Where follow-up data were available, unlike in pure myelopathy, more of these patients had an unfavourable outcome (8 deaths, 4 no improvement) compared with those who improved (8).
| Other
A handful of other neurological disorders have been associated with chikungunya, albeit in smaller numbers. A study from the Réunion outbreak described 32 patients presenting with behavioural changes including attention disorders, irritability, and memory issues. 37 Other reports have described febrile seizures, isolated cranial nerve palsies, stroke, and hearing loss (Table 1) , and one report (in press) describes the possibility of an association with chronic fatigue syndrome.
Although it is difficult to definitively associate these isolated disorders with chikungunya infection, the full spectrum of chikungunya-associated neurological diseases appears to be broad.
| Perinatally acquired neurological disease
Most of the evidence on chikungunya causing neonatal disease relates to transmission in the intrapartum period, rather than earlier in pregnancy. A wide range of severe manifestations has been described affecting neonates whose mothers had acute chikungunya infection near the time of delivery (Table 3) . A case series from Colombia from 2014 to 2015 described 8 infants who required admission to an intensive care unit after contracting chikungunya infection perinatally. 31 All mothers and neonates were PCR and IgM positive for chikungunya in serum; the neonates presented with severe diseases including meningoencephalitis, respiratory distress, sepsis, necrotising enterocolitis, myocarditis, and pericarditis.
One study from Réunion Island described 739 mothers who experienced symptoms of chikungunya infection during pregnancy, 39 of whom were symptomatic in the intrapartum period (between 2 d before and 2 d after delivery). 105 Of these 39 mothers, all infants were asymptomatic at birth, but 19 developed acute disease a median 4
(range 3-7) days after delivery, giving a vertical transmission rate of approximately 50% for mothers symptomatic in the intrapartum period. The initial clinical features in the affected neonates included fever, distress, poor feeding, petechiae, and a maculopapular rash. Nine cases (47%) were reported to have developed encephalopathy. Cerebrospinal fluid for all 9 showed normal biochemistry and white cell counts, and chikungunya PCR was detected in 5. Magnetic resonance imaging data from this study, combined with a later follow-up study, 120 show that amongst neonates developing encephalopathy or encephalitis after perinatally acquired chikungunya, severe white matter injury is well characterised in a 3-stage pattern: cytotoxic brain oedema (ischaemia), vasogenic oedema (reperfusion), and mass reduction (demyelination). 105, 120 In addition to these severe features, hypotonia has been described in 17 neonates with chikungunya infection from Réunion Island, 97 as well as intracerebral haemorrhage secondary to clotting abnormalities. 105, 112 Interestingly, neonatal spinal cord and peripheral nervous system diseases have not been reported.
With regard to prevention of transmission, no studies have found a protective effect of caesarean section. 105, 114 The risk factors for vertical transmission are not understood, although in one study, the viral load of chikungunya in the placentas of the 19 transmitters was found to be significantly higher than in 13 nontransmitters. 105 Interestingly, one of the transmitters gave birth to dizygous twins, of whom one acquired infection but the other did not.
In addition to overt diseases in some perinatally infected neonates soon after delivery, there is also evidence for impacts on longer-term development. In one study comparing the neurocognitive function at approximately 2 years of age for 33 children with and 135 without perinatal chikungunya infection, significant differences in development quotients were found, including movement, coordination, language, and sociability. 120 Importantly, even those infected at birth without obvious clinical features of neurological disease, such as encephalopathy, had significantly worsened neurocognitive function than uninfected children. Thus, the neurological effects of vertically transmitted chikungunya may not be obvious at birth, emphasising the importance of follow-up of this cohort. The 12 cases with encephalopathy at birth showed still more severe developmental deficit, including cerebral palsy and microcephaly.
Maternal chikungunya virus infection earlier in pregnancy does not appear to affect the fetus; in the above study investigating 739 mothers with chikungunya infection, 700 were symptomatic outside of the intrapartum period, and none of these infants developed symptoms of chikungunya. no difference in the rate of congenital malformations. 123 Adverse outcomes in neonates following perinatal dengue infection, such as thrombocytopenia, dengue haemorrhagic fever, and dengue shock syndrome, have been described in a handful of case reports and series in neonates [124] [125] [126] ; but unlike chikungunya and Zika, apart from one case of anoxic encephalopathy, 127 neurological complications have not been reported.
| Pathophysiology
The mechanisms by which chikungunya virus affects the nervous sys- A study from India compared the cytokine profile for patients with and without neurological complications following chikungunya infection. 128 Of those with neurological disease, 4 had encephalitis and 1 Patient had a subarachnoid haemorrhage and optic atrophy in addition to encephalitis.
had "neuropathy." Concentrations of 4 cytokines (TNF-α, IFN-α, IL-6, and monokine induced by IFN-γ) were found to be significantly higher in patients with neurological disease secondary to chikungunya, as opposed to uncomplicated chikungunya infection. However, the role of these cytokines in disease pathogenesis is still unclear.
Whether the virus affects the nervous system directly or indirectly via a triggered immune-mediated effect is also unknown; scarce evidence argues for both. For the former, both RNA and virus have been isolated from CSF in severe CNS disease, 30 consistent with direct neuroinvasion. Neurons, astrocytes, and oligodendrocytes (but not microglia) are susceptible to chikungunya infection in vitro; the former 2 cell types were shown to undergo apoptosis postinfection. 129, 130 In vivo, subcutaneous inoculation in macaques resulted in morphological changes in astrocytes, including cell body hypertrophy and alteration in the pattern of branching of their primary processes. 131 In relation to the latter, immune-mediated hypothesis, this study also showed upregulation of TLR2 in grey matter astrocytes, a gene associated with the innate immune response. The clinical neurological state of the macaques was not reported, which adds to the uncertainty of whether the immune response was protective or pathogenic in these cases. Another study that subcutaneously inoculated mice with chikungunya virus detected upregulation of TLR3 in the brain, a gene that is also associated with the innate immune response. 132 Amongst other clinical signs, these mice developed hind-limb paralysis, dehydration, and weight loss, and 25% of them died after 1 week. Interestingly, pretreatment with polyinosinic:
polycytidylic acid (a TLR3 agonist and interferon inducer), which caused upregulation of proinflammatory cytokines, chemokines, antiviral genes, and IFN-β, was protective clinically and promoted viral clearance from the brain, arguing for a protective innate and adaptive immune response, at least in CNS disease. In concordance, faster viral clearance after chikungunya infection was seen in wild-type mice compared with a TLR3-knockout model; this was thought to be secondary to increased antibody-neutralising activity in the wild-type mice. 133 Chikungunya-infected TLR3-knockout mice had increased viral dissemination throughout the viscera, including the brain. Along with a U-shaped pattern of age-specific incidence, this critical role of TLR3 is reminiscent of susceptibility to HSV encephalitis.
Patients diagnosed with myeloneuropathy or encephalo myeloneuropathy exhibit disease of both the CNS and peripheral nervous system. Given the association between chikungunya and GBS, it is not clear whether in these cases, there is one underlying pathological process involving both the CNS and peripheral nerves, or dual pathology, with a myelopathy ± encephalopathy centrally and GBS peripherally. For example, a case report from India described a 73-year-old man who, a week after chikungunya infection, was admitted with drowsiness, weakness, and absent reflexes and eventually died. 34 His CSF and MRI showed evidence of CNS involvement, and an electromyogram showed a sensorimotor neuropathy. A brain autopsy showed subarachnoid haemorrhage, ischaemic changes, and small foci of demyelination without identification of viral inclusion bodies. Clearly, this patient had involvement of both CNS and peripheral nervous system at the same time, but it is not clear whether the same pathological process was responsible for both. Elucidation of these mechanisms may help to better guide management strategies.
Neurological disease secondary to chikungunya has been reported in areas with both ECSA (or ECSA-diverged Indian Ocean lineage) and Asian strains, but whether these strains have differing neurovirulence is unknown. One study compared the effect of intracerebral inoculation of Asian and ECSA-diverged strains in mice. 134 Both spread within the brain to a similar extent, but the Asian strain was associated with higher mortality than the ECSA-diverged strain. Upregulation of a gene associated with apoptosis was seen in the former, whilst antiapoptosis, antiviral, and CNS protective gene upregulation were seen in the latter.
This potentially suggests a higher neurovirulence of the Asian strain, and comparative clinical data from countries such as Brazil, where both strains are circulating, will be useful.
On neonatal neurological disease, given that caesarean section is not protective, vertical transmission is unlikely to occur via the birth canal, as is the case in other neonatal infections such as herpes simplex. 135 Furthermore, the placenta seems to act as a barrier to transmission, as one study reported (as unpublished data) that placental cells from infected neonates were negative when labelled with antichikungunya antibody. 105 One hypothesis raised by the authors is that uterine contractions result in breaches of this placental barrier, allowing passive passage of the virus.
| Management
There are currently no specific antiviral agents or vaccines for chikungunya virus. 136 Various in vitro compounds active against chikungunya virus have been reported, including both direct-acting and host-targeting antivirals; however, most of these compounds have yet to find their way into in vivo models and clinical trials. 137 Two of the few that have been tested clinically, chloroquine and ribavirin, are already widely used in the treatment of other diseases and have a known safety profile. However, chloroquine was found not to have any benefit for arthritic chikungunya when compared with a nonsteroidal anti-inflammatory drug in a randomised clinical trial. 138 Ribavirin, on the other hand, had promising results in a small case series of 10 patients with severe arthritis post-chikungunya infection. 139 To the best of our knowledge, no antiviral has been evaluated in the management of chikungunya-associated neurological disease, which therefore remains the same as that of neurological disease without associated chikungunya infection: for patients with encephalitis, those with a reduced Glasgow coma score (GCS) require assessment by intensive care specialists and may need intubation, ventilatory support, correction of electrolyte abnormalities, management of raised intracranial pressure, and enhancement of cerebral perfusion pressure. 140 In patients with myelitis, corticosteroids are the standard first-line treatment, despite the lack of trial evidence for their use in this scenario. 141 The management of GBS focuses on immunotherapy with intravenous immunoglobulin or plasma exchange, and ventilatory support if the innervation of respiratory muscles is affected. 109 Although not yet commercially available, it is hoped that a vaccine for chikungunya is on the horizon. Two phase 1 clinical trials have shown a good safety and immunogenicity profile to date. 142, 143 A recent study that tested an insect-specific alphavirus as the vaccine platform found promising results in mice and macaques, including immunogenicity after a single dose. with acute neurological disease and all mothers presenting with fever, arthralgia, or rash; neonates with suspected infection should be followed up for at least 2 years for evidence of neurodevelopmental delay, regardless of the initial presentation (Table 4) . Future challenges include understanding the full scope of chikungunya neurological disease, in both neonatal and adult infection, and their underlying pathophysiological mechanisms. It is hoped that new direct therapeutic and vaccine candidates, some of which have shown promise in early studies, will augment the current supportive management strategies.
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